Abstract
The standard version of the wing somatic mutation and recombination test (SMART) in Drosophila melanogaster was employed in order to evaluate the genotoxic potential of metronidazole (MTZ) as a function of exposure concentration. MTZ was administered by chronic feeding of 3-day-old larvae with the parenteral solution at 0, 500, 1000 and 2000 μg/ml until pupation. The marker-heterozygous progeny (mwh+/+flr3) with phenotypically wild-type wings was analyzed. Non significant differences were found between control and each MTZ concentration tested for single small spots (SSS) frequencies. Large single spots (LSS) and twin spots (TS) were significantly increased with the higher dose. MTZ treatments with 1000 and 2000 μg/ml also significantly increased the frequency of Total spots. These findings suggest that MTZ is genotoxic in the present experimental conditions and induces recombinagenesis and/or gene conversion, two major mechanisms that cause loss of heterocigosity and could play an important role in tumorigenesis and carcinogenesis processes.
Keywords: Drosophila, genotoxicity, metronidazole (MTZ), loss of heterozygosity, wing spot assay.
Current Drug Safety
Title:Metronidazole Induced DNA Damage in Somatic Cells of Drosophila melanogaster
Volume: 8 Issue: 3
Author(s): Ana Maria Palermo and Marta Dolores Mudry
Affiliation:
Keywords: Drosophila, genotoxicity, metronidazole (MTZ), loss of heterozygosity, wing spot assay.
Abstract: The standard version of the wing somatic mutation and recombination test (SMART) in Drosophila melanogaster was employed in order to evaluate the genotoxic potential of metronidazole (MTZ) as a function of exposure concentration. MTZ was administered by chronic feeding of 3-day-old larvae with the parenteral solution at 0, 500, 1000 and 2000 μg/ml until pupation. The marker-heterozygous progeny (mwh+/+flr3) with phenotypically wild-type wings was analyzed. Non significant differences were found between control and each MTZ concentration tested for single small spots (SSS) frequencies. Large single spots (LSS) and twin spots (TS) were significantly increased with the higher dose. MTZ treatments with 1000 and 2000 μg/ml also significantly increased the frequency of Total spots. These findings suggest that MTZ is genotoxic in the present experimental conditions and induces recombinagenesis and/or gene conversion, two major mechanisms that cause loss of heterocigosity and could play an important role in tumorigenesis and carcinogenesis processes.
Export Options
About this article
Cite this article as:
Palermo Maria Ana and Mudry Dolores Marta, Metronidazole Induced DNA Damage in Somatic Cells of Drosophila melanogaster, Current Drug Safety 2013; 8 (3) . https://dx.doi.org/10.2174/15748863113089990035
DOI https://dx.doi.org/10.2174/15748863113089990035 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
XSTING, Software for Evaluation of Radiotherapy Planning Performed Using EGSnrcMP Codes
Current Medical Imaging Labelling and Tracking of Human Mesenchymal Stromal Cells in Preclinical Studies and Large Animal Models of Degenerative Diseases
Current Stem Cell Research & Therapy Applications of Artificial Neural Networks in Medical Science
Current Clinical Pharmacology Hypothyroidism and Cardiovascular Disease: Factors, Mechanism and Future Perspectives
Current Medicinal Chemistry Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials
Current Drug Metabolism Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Dietary Assumption of Plant Polyphenols and Prevention of Allergy
Current Pharmaceutical Design Proteasome Inhibition: A Promising Strategy for Treating Cancer, but What About Neurotoxicity?
Current Medicinal Chemistry Cerenkov Luminescence Imaging at a Glance
Current Molecular Imaging (Discontinued) The Evaluation of Animal Models in the Development of Anticancer Agents: From Preclinical to Clinical Tests
Current Cancer Drug Targets Current Perspectives of Healthy Mitochondrial Function for Healthy Neurons
Current Drug Targets Recent Developments in Targeting Bromodomain and Extra Terminal Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry Bilski: Assessing the Impact of a Newly Invigorated Patent-Eligibility Doctrine on the Pharmaceutical Industry and the Future of Personalized Medicine
Current Topics in Medicinal Chemistry Learning from Nature: Bioinspired Strategies Towards Antimicrobial Nanostructured Systems
Current Topics in Medicinal Chemistry Epidemiology of Major Congenital Malformations with Specific Focus on Teratogens
Current Drug Safety Substrate Specificity, Regulation, and Polymorphism of Human Cytochrome P450 2B6
Current Drug Metabolism Ultrasound and Microbubble Guided Drug Delivery: Mechanistic Understanding and Clinical Implications
Current Pharmaceutical Biotechnology Beneficial Action of Citrus Flavonoids on Multiple Cancer-Related Biological Pathways
Current Cancer Drug Targets Structural Heterogeneity and Multifunctionality of Lactoferrin
Current Protein & Peptide Science